Pacific Edge Investment for Growth Delivers Early Results: Operating revenue from test sales increased 62% to $8.7 million in the half year to 30 September 2022, with total laboratory throughput rising 34% to 14,917 tests.
Net losses after tax increased to $10.6 million, as Pacific Edge continues to invest for growth, with cash, cash equivalents and short-term deposits at $93.5 million.
The company is making progress with Kaiser Permanente in the US, while expanding into new markets such as Australia and Singapore.
The outlook is optimistic, tempered by proposed changes to Medicare reimbursement.
See more
